Last reviewed · How we verify
Reiferon retard
Reiferon retard is a long-acting formulation of interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth.
Reiferon retard is a long-acting formulation of interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).
At a glance
| Generic name | Reiferon retard |
|---|---|
| Also known as | Pegylated interferon α 2a |
| Sponsor | MinaPharm Pharmaceuticals |
| Drug class | Interferon alfa-2a (long-acting/sustained-release formulation) |
| Target | Type I interferon receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Interferon alfa-2a binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. The retard (sustained-release) formulation extends the half-life, allowing for less frequent dosing while maintaining therapeutic interferon levels. This mechanism makes it effective against chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Injection site reactions
Key clinical trials
- Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV (NA)
- Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population (PHASE4)
- Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV) (PHASE2, PHASE3)
- Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reiferon retard CI brief — competitive landscape report
- Reiferon retard updates RSS · CI watch RSS
- MinaPharm Pharmaceuticals portfolio CI